To compare pramipexole to escitalopram in the treatment of major depressive disorder in people living with HIV.
This study will look at how well an injectable treatment works for people with detectable levels of HIV who are taking oral antiretroviral therapy (ART). This study will also check if the treatment is safe, how long it lasts, and ask about people’s experience.
The purpose of this study is to see if an experimental vaccine called CH505 TF chTrimer is safe and well tolerated in people living with human immunodeficiency virus (HIV) and to see if it will help the body's immune system respond to HIV.
The primary objective of the study is to evaluate the efficacy of switching to oral weekly ISL/LEN tablet regimen versus continuing standard of care in virologically suppressed PWH at Week 48.
This study will test whether a single dose of antibodies can help prevent COVID-19 from getting worse in high-risk adult patients recently diagnosed with COVID-19.
This study wants to see if gut problems are worse in HIV+ men that have sex with men that have metabolic syndrome compared those without metabolic syndrome.
To evaluate the health and wellbeing of women living with HIV of reproductive age utilizing innovative epidemiologic study designs and cost-effective methods for enrollment, follow-up and data collection
To find out if bNAbs, VRC07-523LS and PGT121.414.LS, are safe for administration with ART. To evaluate if the bNAbs are effective at keeping HIV from reproducing. It is necessary to stop taking ART after receiving the bNAbs or placebos for bNAbs. This is referred to as an ATI (analytical treatment interruption).
The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have been receiving suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study will also evaluate if TLR8 stimulation with SLGN will reduce hepatitis ...